{"name":"Instituto Bioclon S.A. de C.V.","slug":"instituto-bioclon-s-a-de-c-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Anascorp","genericName":"Anascorp","slug":"anascorp","indication":"Other","status":"marketed"},{"name":"Analatro","genericName":"Analatro","slug":"analatro","indication":"Other","status":"phase_3"},{"name":"Anavip","genericName":"Anavip","slug":"anavip","indication":"Other","status":"marketed"},{"name":"Antivipmyn ®","genericName":"Antivipmyn ®","slug":"antivipmyn","indication":"Envenomation from venomous snakes and other venomous animals","status":"marketed"},{"name":"CroFab","genericName":"CroFab","slug":"crofab","indication":"Envenomation by North American crotalid snakes (rattlesnakes, cottonmouths, copperheads)","status":"marketed"}]}],"pipeline":[{"name":"Anascorp","genericName":"Anascorp","slug":"anascorp","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Analatro","genericName":"Analatro","slug":"analatro","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anavip","genericName":"Anavip","slug":"anavip","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Antivipmyn ®","genericName":"Antivipmyn ®","slug":"antivipmyn","phase":"marketed","mechanism":"Antivipmyn is an antivenom that neutralizes venom toxins by binding to and inactivating specific venom components through antibody-antigen interactions.","indications":["Envenomation from venomous snakes and other venomous animals"],"catalyst":""},{"name":"CroFab","genericName":"CroFab","slug":"crofab","phase":"marketed","mechanism":"CroFab is a polyclonal antivenom that binds and neutralizes venom toxins from North American crotalid snakes (rattlesnakes, cottonmouths, and copperheads).","indications":["Envenomation by North American crotalid snakes (rattlesnakes, cottonmouths, copperheads)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQbXRwRHJYdERkSGtkTDJ2cjJ1d2xwQ1hPUm82aVY5Rnl0aGFRQWdFeldqOEFpd1VVUjFtMzBPOG10bHl4LW00cTNIY2FDOGZISDF1djY1S25MWlBrb0hTY0VEcy1zZlNBZnNtdXJaWDQ1NEVQelRld1NRX1BJSEk4Rk45eDl4WkZyU1Y2QXExbDI1YlhSYXBnR2pJYlhsVml1dVRBYVlqbnBtUDRKTWFOOE8zcHBuNkdyLXp3MG5GUkRMTURlM2c?oc=5","date":"2025-04-11","type":"pipeline","source":"BioSpace","summary":"Anti-Venom Market Size to Hit USD 2,495.7 Million by 2032, says Coherent Market Insights - BioSpace","headline":"Anti-Venom Market Size to Hit USD 2,495.7 Million by 2032, says Coherent Market Insights","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":4,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}